Diurnal cortisol dysregulation, functional disability, and depression in women with ovarian cancer

Cancer

Volumn 116, Issue 18, 2010, Pages 4410-4419

  Weinrib, Aliza Z ^a   Sephton, Sandra E ^b   DeGeest, Koen ^c   Penedo, Frank ^d   Bender, David ^c   Zimmerman, Bridget ^e   Kirschbaum, Clemens ^f   Sood, Anil K ^g   Lubaroff, David M ^a,c   Lutgendorf, Susan K ^a,c  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d Department of Biology   (United States)

^e UNIVERSITY OF IOWA HEALTH CARE   (United States)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^g UNIVERSITY OF TEXAS   (United States)

Author keywords

Cortisol; Depression; Diurnal rhythm; Fatigue; Functional disability; Ovarian cancer; Stress

Indexed keywords

HYDROCORTISONE;

ADULT; ARTICLE; CANCER GROWTH; CIRCADIAN RHYTHM; DEPRESSION; FATIGUE; FEMALE; FUNCTIONAL DISEASE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LIFE STRESS; MAJOR CLINICAL STUDY; MENTAL STRESS; OVARY CANCER; PRIORITY JOURNAL; AGED; COMPLICATION; DAILY LIFE ACTIVITY; HEALTH STATUS; METABOLISM; MIDDLE AGED; OVARY TUMOR; PATHOPHYSIOLOGY; QUALITY OF LIFE; SALIVA;

ACTIVITIES OF DAILY LIVING; AGED; CIRCADIAN RHYTHM; DEPRESSION; FATIGUE; FEMALE; HEALTH STATUS; HUMANS; HYDROCORTISONE; MIDDLE AGED; OVARIAN NEOPLASMS; QUALITY OF LIFE; SALIVA; STRESS, PSYCHOLOGICAL;

EID: 77957357797     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25299     Document Type: Article

References (58)

1. Sephton S, Spiegel D. Circadian disruption in cancer: a neuroendocrine-immune pathway from stress to disease? Brain Behav Immun. 2003;17:321-328.
2. Touitou Y, Bogdan A, Levi F, Benavides M, Auzeby A. Disruption of the circadian patterns of serum cortisol in breast and ovarian cancer patients: relationships with tumour marker antigens. Br J Cancer. 1996;74:1248-1252.
3. Touitou Y, Levi F, Bogdan A, Benavides M, Bailleul F, Misser J-L. Rhythm alteration in patients with metastatic breast cancer and poor prognostic factors. J Cancer Res Clin. 1995;121:181-188.
4. Bower JE, Ganz PA, Dickerson SS, Petersen L, Aziz N, Fahey JL. Diurnal cortisol rhythm and fatigue in breast cancer survivors. Psychoneuroendocrinology. 2005;30:92-100.
5. Sephton S, Sapolsky RM, Kraemer HC, Speigel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst. 2000;92:994-1000.
6. Buijs RM, van Eden CG, Goncharuk VD, Kalsbeek A. Circadian and season rhythms: the biological clock tunes the organs of the body: timing by hormones and the autonomic nervous system. J Endocrinol. 2003;177:17-26.
7. Kirschbaum C, Hellhammer DH. Salivary cortisol. In: Fink G, ed. Encyclopedia of Stress. Vol 3. Burlington, MA: Academic Press; 2000.
8. Maier S, Watkins L. Cytokines for psychologists: implications of bidirectional immune to brain communication for understanding behavior, mood, and cognition. Psychol Rev. 1998;105:83-107.
9. Kirschbaum C, Hellhammer DH. Salivary cortisol in psychobiological research: an overview. Neuropsychobiology. 1989;22:150-169.
10. Smyth J, Ockenfels M, Gorin A, et al. Individual differences in the diurnal cycle of cortisol. Psychoneuroendocrinology. 1997;22:89-105.
11. Sapolsky RM, Alberts SC, Altmann J. Hypercortisolism associated with social subordinance or social isolation among wild baboons. Arch Gen Psychiatry. 1997;54:1137-1143.
12. Chrousos GP, Gold PW. A healthy body in a healthy mind-and vice versa-the damaging power of "uncontrollable" stress. J Clin Endocrinol Metab. 1998;83:1842-1845.
13. Deuschle M, Schweiger U, Weber B, et al. Diurnal activity and pulsatility of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls. J Clin Endocrinol Metab. 1997;82:234-238.
14. Jehn CF, Kuehnhardt D, Bartholomae A, et al. Biomarkers of depression in cancer patients. Cancer. 2006;107:2723-2729.
15. Turner-Cobb J, Sephton S, Koopman C, Blake-Mortimer J, Spiegel D. Social support and salivary cortisol in women with metastatic breast cancer. Psychosom Med. 2000;62:337-345.
16. Sapolsky RM, Donnelly TM. Vulnerability to stress-induced tumor growth increases with age in rats: role of glucocorticoids. Endocrinology. 1985;117:662-666.
17. Filipski E, King VM, Li X, et al. Host circadian clock as a control point in tumor progression. J Natl Cancer Inst. 2002;94:690-697.
18. Schernhammer ES, Laden F, Speizer FE, et al. Rotating night shifts and risk of breast cancer in women participating in nurses' health study. J Natl Cancer Inst. 2001;93:1563-1568.
19. Mormont MC, Levi F. Circadian-system alterations during cancer processes: a review. Int J Cancer. 1997;70:241-247.
20. Lutgendorf SK, Weinrib AZ, Penedo F, et al. Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J Clin Oncol. 2008;26:4820-4827.
21. Thakore JH, Barnes C, Joyce J, Medbak S, Dinan TG. Effects of anti-depressant treatment on corticotropin-induced cortisol responses in patients with melancholic depression. Psychiatry Res. 1997;73:27-32.
22. Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Ovarian. J Clin Oncol. 2001;19:1809-1817.
23. Gynecologic Oncology Group Protocol Procedures Manual. Appendix 10. November 2005.
24. McNair DM, Lorr M, Droppelman LF. EdiTS Manual for the Profile of Mood States. San Diego, CA: EITS; 1992.
25. Andersen B, Anderson B, deProsse C. Controlled prospective longitudinal study of women with cancer: I. Psychological functioning and outcomes. J Consult Clin Psychol. 1989;57:683-691.
26. Radloff L. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385-401.
27. Sheehan TJ, Fifield J, Reisine S, Tennen H. The measurement structure of the Center for Epidemiologic Studies depression scale. J Pers Assess. 1995;64:507-521.
28. Cohen S, Kamarck T, Mermelstein R. Global measure of perceived stress. J Health Hum Behav. 1983;24:385-396.
29. Stone AA, Mezzacappa E, Donatone B, Gonder M. Psychosocial stress and social support are associated with prostate-specific antigen levels in men: results from a community screening program. Health Psychol. 1999;18:482-486.
30. Sarason IG, Johnson JH, Siegel JM. Assessing the impact of life changes: development of the Life Experiences Survey. J Consult Clin Psychol. 1978;46:932-946.
31. Leserman J, Whetten K, Lowe K, Stangl D, Swartz MS, Thielman NM. How trauma, recent stressful events, and PTSD affect functional health status and health utilization in HIV-infected patients in the south. Psychosom Med. 2005;67:500-507.
32. Kraemer HC, Giese-Davis J, Yutsis M, et al. Design decisions to optimize reliability of daytime cortisol slopes in an older population. Am J Geriatr Psychiatry. 2006;14:325-333.
33. Giese-Davis J, Wilhelm FH, Conrad A, et al. Depression and stress reactivity in metastatic breast cancer. Psychosom Med. 2006;68:675-683.
34. Deuschle M, Gotthardt U, Schweiger U, et al. With aging in humans the activity of the hypothalamus-pituitary-adrenal system increases and its diurnal amplitude flattens. Life Sci. 1997;61:2246-2249.
35. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22.
36. File SE. Interactions of anxiolytic and antidepressant drugs with hormones of the hypothalamic-pituitary-adrenal axis. Pharmacol Ther. 1990;46:357-395.
37. Skelton KH, Nemeroff CB, Knight DL, Owens MJ. Chronic administration of the triazolobenzodiazepine alprazolam produces opposite effects on corticotropin-releasing factor and urocortin neuronal systems. J Neurosci. 2000;20:1240-1248.
38. Abercrombie HC, Giese-Davis J, Sephton S, Epel ES, Turner-Cobb JM, Spiegel D. Flattened cortisol rhythms in metastatic breast cancer patients. Psychoneuroendocrinology. 2004;29:1082-1092.
39. Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry. 2003;160:1554-1565.
40. McCain GA, Tilbe KS. Diurnal hormone variation in fibromyalgia syndrome: a comparison with rheumatoid arthritis. J Rheumatol. 1989(19 suppl):154-157.
41. Nater UM, Youngblood LS, Jones JF, et al. Alterations in diurnal salivary cortisol rhythm in a population-based sample of cases with Chronic Fatigue Syndrome. Pyschosomatic Medicine. 2008;70:298-305.
42. Baxter JD, Frohman LA, Felig P. Introduction to the endocrine system. In: Felig P, Baxter JD, Frohman LA, eds. Endocrinology and Metabolism. 3rd ed. New York, NY: McGraw-Hill; 1995:3-20.
43. Spiegel D, Giese-Davis J, Taylor CB, Kraemer H. Stress sensitivity in metastatic breast cancer: analysis of hypothalamic-pituitary-adrenal axis function. Psychoneuroendocrinology. 2006;31:1231-1244.
44. Watson JM, Sensintaffar JL, Berek JS, Martinez-Maza O. Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res. 1990;50:6959-6965.
45. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med. 1995;332:1351-1362.
46. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9:46-57.
47. Hughes JW, Watkins L, Blumenthal JA, Kuhn C, Sherwood A. Depression and anxiety symptoms are related to increased 24-hour urinary norepinephrine excretion among healthy middle-aged women. J Psychosom Res. 2004;57:353-358.
48. Nilsson MB, Armaiz-Pena G, Takahashi R, et al. Stress hormones regulate IL-6 expression by human ovarian carcinoma cells through a SRC-dependent mechanism. J Biol Chem. 2007;282:29919-29926.
49. Cavadini G, Petrzilka S, Kohler P, et al. TNF-alpha suppresses the expression of clock genes by interfering with E-box-mediated transcription. Proc Natl Acad Sci U S A. 2007;104:12843-12848.
50. Ohdo S, Koyanagi S, Suyama H, Higuchi S, Aramaki H. Changing the dosing schedule minimizes the disruptive effects of interferon on clock function. Nat Med. 2001;7:356-360.
51. Kronfol Z, Nair M, Zhang Q, Hill EE, Brown MB. Circadian immune measures in healthy volunteers: relationship to hypothalamic-pituitary-adrenal axis hormones and sympathetic neurotransmitters. Psychosom Med. 1997;59:42-50.
52. Sephton SE, Dhabhar FS, Keuroghlian AS, et al. Depression, cortisol, and suppressed cell-mediated immunity in metastatic breast cancer. Brain Behav Immun. 2009;23:1148-1155.
53. Mormont M-C, Hecquet B, Bogdan A, Benavides M, Touitou Y, Levi F. Non-invasive estimation of the circadian rhythm in serum cortisol in patients with ovarian or colorectal cancer. Int J Cancer. 1998;78:421-424.
54. Levi F. Circadian chronotherapy for human cancers. Lancet. 2001;2:307-315.
55. Moran TJ, Gray S, Mikosz CA, Conzen SD. The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells. Cancer Res. 2000;60:867-872.
56. Antonova L, Mueller CR. Hydrocortisone down-regulates the tumor suppressor gene BRCA1 in mammary cells: a possible molecular link between stress and breast cancer. Genes Chromosomes Cancer. 2008;47:341-352.
57. Pang D, Kocherginsky M, Krausz T, Kim SY, Conzen SD. Dexamethasone decreases xenograft response to Paclitaxel through inhibition of tumor cell apoptosis. Cancer Biol Ther. 2006;5:933-940.
58. Johansson AC, Gunnarsson LG, Linton SJ, et al. Pain, disability and coping reflected in the diurnal cortisol variability in patients scheduled for lumbar disc surgery. Eur J Pain. 2008;12:633-640.